Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.

The demographics of the participants is shown in Table 1 , and in general, they were similar across the groups, except for the male to female ratio between high- and low-dose ECV-19 groups, which was barely significant ( p = 0.0474 by Fisher’s exact test with Bonferroni correction).

also in 875 other papers